The Lead Episode 123: A Discussion of Re-Ablation of Atrial Fibrillation Targeting Electrogram Dispersion – The RESTART Trial LIVE at HRX

Article for Discussion: Re-Ablation in Patients with Documented Isolated Veins Using a Tailored Approach Targeting Electrogram-Dispersion: The RESTART Trial

Join host and HRS Digital Education Committee Vice-Chair, Tina Baykaner, MD, MPH and her guests Jerome Kalifa, MD and Paul C. Zei, MD, PhD, FHRS as they discuss this article at HRX 2025 in Atlanta.

The RESTART trial is an international, multicenter, non-randomized interventional study designed to assess whether using Volta Medical’s AI-assisted algorithm to identify and ablate dispersed electrograms (EGMs) in addition to doing repeat pulmonary vein isolation can improve outcomes in patients whose atrial fibrillation recurred after previous ablations. The main goal is to see the proportion of patients who are free from AF twelve months after the repeat procedure (without antiarrhythmic drugs), and the trial contains about 92 patients.

Learning Objective: Describe the design and purpose of the RESTART trial, including how the use of AI-guided identification and ablation of dispersed electrograms aims to improve outcomes for patients undergoing repeat ablation for recurrent atrial fibrillation.

Podcast Contributors

Jerome Kalifa, MD
Paul C. Zei, MD, PhD, FHRS
Tina Baykaner, MD, MPH

Speaker and Article Information: Download

Listen on Heart Rhythm 365
Listen on the Innovation Hub
Listen on Apple Podcasts
Listen on iHeart
Listen on Spotify